financetom
Business
financetom
/
Business
/
Federal Bank Q1FY22: Net profit falls 8.4% to Rs 367.29 cr
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Federal Bank Q1FY22: Net profit falls 8.4% to Rs 367.29 cr
Jul 23, 2021 8:01 AM

Private sector lender Federal Bank on Friday reported an 8.4 percent fall in its net profit to Rs 367.29 crore for the first quarter ended June 30, 2021, as provisioning for bad loans soared. The bank had posted a net profit of Rs 400.77 crore in the corresponding quarter of the previous financial year.

On a sequential basis also, the net profit was down 23.1 percent, from Rs 477.81 crore in the quarter ended March 2021. However, its total income during April-June 2021 was higher at Rs 4,005.86 crore as against Rs 3,932.52 crore in the year-ago period, Federal Bank said in a regulatory filing.

The bank's asset quality showed deterioration as the gross non-performing assets (NPAs) rose to 3.50 percent of the gross advances by the end of June 2021, from 2.96 percent as of June 2020. Net NPAs or bad loans, however, remained stable at 1.23 percent as against 1.22 percent a year ago.

Provisioning for bad loans and contingencies for the June 2021 quarter spiked substantially to Rs 641.83 crore, from Rs 394.62 crore in year-ago period. The bank said its board of directors also approved allotment of 10,48,46,394 equity shares at an issue price of Rs 87.39 apiece to International Finance Corporation (IFC) and its related entities for Rs 916.25 crore.

It has allotted 31,453,918 shares to IFC; and 36,696,238 each to IFC Financial Institutions Growth Fund, LP (FIG) and IFC Emerging Asia Fund, LP (EAF). With the allotment of these shares, the bank's paid-up equity share capital stands increased from the current level of 199,62,83,783 equity shares to 210,11,30,132 equity shares of Rs 2 each, Federal Bank said.

The bank's shares on Friday traded 1.36 percent higher at Rs 85.40 apiece on the BSE.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Safety Shot Rebrands as Sure Shot
Safety Shot Rebrands as Sure Shot
Oct 9, 2024
08:59 AM EDT, 10/09/2024 (MT Newswires) -- Safety Shot ( SHOT ) said Wednesday it has rebranded as Sure Shot. The company said it teamed up with full-service agency Amalgam, which led the rebranding effort in partnership with Stout Design. Price: 1.2795, Change: +0.02, Percent Change: +1.55 ...
Theratechnologies to Present Data Next Week Highlighting Advances in Treatment in People with HIV
Theratechnologies to Present Data Next Week Highlighting Advances in Treatment in People with HIV
Oct 9, 2024
08:01 AM EDT, 10/09/2024 (MT Newswires) -- Theratechnologies ( THTX ) on Wednesday announced three poster presentations at IDWeek 2024 taking place next week in Los Angeles. One poster presents data linking excess visceral abdominal fat (EVAF) to increased cardiovascular risk in people with HIV, while a second poster documents how use of tesamorelin, a growth hormone-releasing factor analog, to...
Hyundai to use $3 bln record India IPO proceeds for new cars, R&D
Hyundai to use $3 bln record India IPO proceeds for new cars, R&D
Oct 9, 2024
* Hyundai IPO biggest ever in India, Asia's biggest in 2024 * Company wants to expand in India; first listing outside S.Korea * Hyundai aims to make India a manufacturing hub for emerging mkts * Executive says 30% increase in production seen in 3-4 years (Adds details, comments in paragraph 7, 11, 16-17) By Dhwani Pandya MUMBAI, Oct 9 (Reuters)...
Capricor Therapeutics Submits Biologics License Application to FDA for Duchenne Muscular Dystrophy Drug Candidate
Capricor Therapeutics Submits Biologics License Application to FDA for Duchenne Muscular Dystrophy Drug Candidate
Oct 9, 2024
10:00 AM EDT, 10/09/2024 (MT Newswires) -- Capricor Therapeutics ( CAPR ) said Wednesday that it has initiated a rolling submission with the US Food and Drug Administration for a biologics license application for deramiocel to treat patients with Duchenne muscular dystrophy cardiomyopathy. The biotech company said it expects to complete the rolling submission by the end of the year...
Copyright 2023-2025 - www.financetom.com All Rights Reserved